miR-34C Disrupts the Stemness of Purified CD133+ Prostatic Cancer Stem Cells

被引：8

作者：

Chen, Yuan

Rao, Qun

Zhang, Huiping

Xu, Hua

Zhang, Cuntai

Zhuang, Qianyuan

Ye, Zhangqun ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, Wuhan 430030, Peoples R China

来源：

UROLOGY | 2016年 / 96卷

关键词：

ANDROGEN RECEPTOR; THERAPY; IDENTIFICATION; EXPRESSION; RESISTANCE; MICRORNA; PROMOTES;

D O I：

10.1016/j.urology.2016.07.021

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

OBJECTIVE To find the potential micro-RNA (miRNA) that could determine the fate of prostate cancer stem cells. MATERIALS AND METHODS We compared miRNA expression between our purified CD133(+) prostatic cancer stem cells (PCSCs) and CD133-cells. Sphere formation assay and matrigel-based cell invasion assay were applied to determine the stemness of CD133(+) PCSCs after our manipulation of miRNA using miRNA mimic or miRNA inhibitor. RESULTS In this study, we identified that miR-34C was under-expressed in the purified CD133(+) PCSCs and enforced introduction of miR-34C attenuated the stemness of CD133(+) PCSCs. Clinically, we also observed a negative correlation between miR-34C and CD133. CONCLUSION Our data strongly suggest that miR-34C may play essential role in conferring castration resistance by equilibrating PSCS population. (C) 2016 Elsevier Inc.

引用

页码：177.e1 / 177.e9

页数：9

共 50 条

[21] Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease
Salama, Hosny
Zekri, Abdel-Rahman N.
Bahnassy, Abeer A.
Medhat, Eman
Halim, Hanan A.
Ahmed, Ola S.
Mohamed, Ghada
Al Alim, Sheren A.
Sherif, Ghada M.
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (42) : 5297 - 5305
[22] CD34+ and CD133+ cells in cord blood of term newborns
Roumiantsev, Sergey A.
Boyakova, Elena V.
Shutieva, Anisya B.
Mayorova, Olga A.
Roumiantsev, Alexander G.
EXPERIMENTAL HEMATOLOGY, 2008, 36 (07) : S62 - S62
[23] CD133+/Musashi-I+/CD34- neural stem cells in gliomas of different grades
Thon, N.
Grau, S.
Krebs, B.
Kretzschmar, H.
Tonn, J.
Goldbrunner, R.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2006, 24 (08) : 529 - 529
[24] miR-34c disrupts spermatogonial stem cell homeostasis in cryptorchid testes by targeting Nanos2
Huang, Zhenyu
Tang, Dongdong
Gao, Jingjing
Dou, Xianming
Cheng, Peng
Peng, Dangwei
Zhang, Yao
Mao, Jun
Zhang, Li
Zhang, Xiansheng
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2018, 16
[25] Ultrasound microbubbles mediated miR-let-7b delivery into CD133+ ovarian cancer stem cells
Yang, Chaopin
Li, Bingcheng
Yu, Jinsui
Yang, Feng
Cai, Kuan
Chen, Zhiyi
BIOSCIENCE REPORTS, 2018, 38
[26] The tumour suppressor miR-34c targets MET in prostate cancer cells
Hagman, Z.
Haflidadottir, B. S.
Ansari, M.
Persson, M.
Bjartell, A.
Edsjo, A.
Ceder, Y.
BRITISH JOURNAL OF CANCER, 2013, 109 (05) : 1271 - 1278
[27] The role of miR-130b in the regulation of CD133+ cancer stem cells-driven hepatocellular carcinoma
Ma, Stephanie
Chan, Yuen Piu
Lee, Terence
Tang, Kwan Ho
Ng, Irene
Man, Kwan
To, Ka Fai
Zheng, Bo-Jian
Chan, Kwok Wah
Guan, Xin-Yuan
CANCER RESEARCH, 2009, 69
[28] Molecular analysis and comparison of CD34+ and CD133+ very small embryonic-like stem cells purified from umbilical cord blood
Bujko, Kamila
Ciechanowicz, Andrzej K.
Kucia, Magdalena
Ratajczak, Mariusz Z.
CYTOMETRY PART A, 2023, 103 (09) : 703 - 711
[29] Splicing variants of versican in CD133+/CD44+prostate cancer stem cells
Ayla, Sule
Karakoc, Emre
Byrne, Yasemin Yozgat
Parlayan, Cuneyd
Keskin, Ilknur
Karahuseyinoglu, Sercin
Taskiran, Aysegul
Oktem, Gulperi
PATHOLOGY RESEARCH AND PRACTICE, 2024, 260
[30] Interferon-α contributes to combined chemotherapy for CD133+ cancer stem cells in pancreatic cancer
Kuwahata, Taisaku
Hayashi, Tomomi
Ding, Qiang
Matsubara, Shuichiro
Maeda, Koki
Miyazaki, Yumi
Obara, Toru
Haraguchi, Misako
Shinchi, Hiroyuki
Natsugoe, Shoji
Takao, Sonshin
CANCER RESEARCH, 2011, 71

← 1 2 3 4 5 →